News & Updates

Cancer patients report high acceptance of telemedicine

14 Jun 2022 by

Patients with cancer are not averse to telemedicine, reporting satisfaction with their experience, according to a Singapore study. This high acceptance is associated with facilitating conditions such as having necessary resources and perceived improved access.

Cancer patients report high acceptance of telemedicine

14 Jun 2022

Clear guidelines needed for closed-system transfer device use with cancer drugs

13 Jun 2022 by

A survey of Canadian healthcare practitioners reveals a lack of clarity on closed-system transfer device (CSTD) compatibility with oncology biologics, as well as the lack of control drug manufacturers have as a single stakeholder to protect the quality of their products and the safety of patients who use them.

Clear guidelines needed for closed-system transfer device use with cancer drugs

13 Jun 2022

Postresection chemoradiotherapy does not prevent second primary tumours in ESCC

13 Jun 2022

In patients with early esophageal squamous cell carcinoma (ESCC), chemoradiotherapy (CRT) following endoscopic resection (ER) does not seem to reduce the incidence of developing second primary ESCC nor cancers in other organs when compared with ER alone, according to a study.

Postresection chemoradiotherapy does not prevent second primary tumours in ESCC

13 Jun 2022

Cord blood transplantation boosts survival in acute myeloid leukaemia

11 Jun 2022

A single cord blood transplantation confers improved overall survival in adult patients with acute myeloid leukaemia, a recent study has found.

Cord blood transplantation boosts survival in acute myeloid leukaemia

11 Jun 2022

$Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML$

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

10 Jun 2022

Patients with relapsed or refractory FLT3-mutated acute myeloid leukaemia (AML) and with prior exposure to tyrosine kinase inhibitors (TKIs) may benefit from gilteritinib treatment, which leads to better remission and survival outcomes than salvage chemotherapy, a recent study has found.

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

10 Jun 2022

Neurocognitive functions decline after paediatric brain tumour radiotherapy

09 Jun 2022

While children with brain tumours already suffer from impaired neurocognitive functions, radiotherapy appears to worsen these impairments, a new study has found.

Neurocognitive functions decline after paediatric brain tumour radiotherapy

09 Jun 2022

$Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma$

Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma

08 Jun 2022

Ixazomib-dexamethasone (ixa-dex) and pomalidomide-dexamethasone (pom-dex) achieve comparable levels of efficacy and safety in relapsed and refractory multiple myeloma (RRMM) patients who had already been exposed to prior lenalidomide-based regimens, a recent study has found.

Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma

08 Jun 2022

Microwave ablation: a better treatment alternative for NSCLC?

08 Jun 2022 by

In patients with non-small-cell lung cancer (NSCLC), image-guided thermal ablation (IGTA) via microwave ablation (MWA) appears to deliver better survival benefit compared with another IGTA subtype, radiofrequency ablation (RFA), or stereotactic body radiation therapy (SBRT), according to a systematic review and meta-analysis presented at ATS 2022.

Microwave ablation: a better treatment alternative for NSCLC?

08 Jun 2022

Hodgkin lymphoma incidence rising in Asia, HK tops global rise in males

08 Jun 2022 by

The incidence of Hodgkin lymphoma has increased in the past decade, especially in Asian countries, females, and the younger population, a global study has shown.

Hodgkin lymphoma incidence rising in Asia, HK tops global rise in males

08 Jun 2022

Glioblastoma: State-of-the-art therapeutic approaches

07 Jun 2022 by

Glioblastoma multiforme (GBM) is a highly malignant cancer with a median overall survival (OS) of approximately 1 year. At a recent webinar, experts shared keys to effective management of GBM and discussed state-of-the-art therapeutic approaches, including tumour-treating fields (TTFields), fluorescence-guided surgery, as well as intraoperative ultrasound and neuro-navigation integration.

Glioblastoma: State-of-the-art therapeutic approaches

07 Jun 2022

News & Updates

Filter by Specialty:

Specialty:

Cancer patients report high acceptance of telemedicine

Cancer patients report high acceptance of telemedicine

Clear guidelines needed for closed-system transfer device use with cancer drugs

Clear guidelines needed for closed-system transfer device use with cancer drugs

Postresection chemoradiotherapy does not prevent second primary tumours in ESCC

Postresection chemoradiotherapy does not prevent second primary tumours in ESCC

Cord blood transplantation boosts survival in acute myeloid leukaemia

Cord blood transplantation boosts survival in acute myeloid leukaemia

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

Neurocognitive functions decline after paediatric brain tumour radiotherapy

Neurocognitive functions decline after paediatric brain tumour radiotherapy

Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma

Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma

Microwave ablation: a better treatment alternative for NSCLC?

Microwave ablation: a better treatment alternative for NSCLC?

Hodgkin lymphoma incidence rising in Asia, HK tops global rise in males

Hodgkin lymphoma incidence rising in Asia, HK tops global rise in males

Glioblastoma: State-of-the-art therapeutic approaches

Glioblastoma: State-of-the-art therapeutic approaches